Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

3(33.3%)

9Total

Phase 1(6)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02508090Completed

Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin

Role: collaborator

NCT01872936Phase 2Unknown

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Role: lead

NCT01727934Phase 2Unknown

Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

Role: lead

NCT01646489Phase 1Completed

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

Role: lead

NCT01365663Phase 1Completed

Multiple Ascending Dose Study of SPC4955 in Healthy Subjects

Role: lead

NCT01200420Phase 2Completed

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects